NCT01356628View on ClinicalTrials.gov

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 25, 2011

Primary Completion Date

June 1, 2023

Study Completion Date

December 16, 2023

Conditions
Advanced Hepatocellular CarcinomaHCCLiver Cancer
Interventions
DRUG

PD-0332991

PD-0332991, 125mg, 3 cycles

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT01356628 - A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer | Biotech Hunter | Biotech Hunter